TABLE 2.
Link between clinical parameters and risk of developing ABMR (univariable analysis).
| Variables | Patients (n) | Events (n) | HR | 95% CI | P-value |
| Clinicobiological factors | |||||
| Recipient age* | |||||
| ≤Median | 74 | 16 | |||
| >Median | 72 | 15 | 1.01 | 0.50–2.05 | 0.96 |
| Recipient sex | |||||
| Male | 86 | 22 | |||
| Female | 60 | 9 | 0.60 | 0.28–1.31 | 0.20 |
| Donor type | |||||
| Living | 17 | 1 | |||
| Deceased | 129 | 30 | 5.21 | 0.71–38.23 | 0.07 |
| Donor age* | |||||
| ≤Median | 74 | 20 | |||
| >Median | 72 | 11 | 0.49 | 0.23–1.02 | 0.06 |
| No of mismatches A/B/DR/DQ* | |||||
| ≤4 | 80 | 13 | |||
| >4 | 66 | 18 | 2.04 | 1.0–4.16 | 0.05 |
| Delayed graft function | |||||
| No | 130 | 29 | |||
| Yes | 16 | 2 | 0.43 | 0.10–1.79 | 0.24 |
| CNI use (CsA vs. Tac) | |||||
| No | 91 | 6 | |||
| Yes | 55 | 25 | 5.21 | 2.12–12.82 | <0.001 |
| Acute cellular rejection** | |||||
| No | 130 | 25 | |||
| Yes | 16 | 6 | 1.75 | 0.72–4.27 | 0.21 |
| BKPyV DNAemia | |||||
| No | 114 | 23 | |||
| Yes | 32 | 8 | 0.92 | 0.41–2.08 | 0.84 |
| Immunological factors | |||||
| dnDSA | |||||
| No | 96 | 2 | |||
| Yes | 50 | 29 | 31.95 | 7.62–133.98 | <0.001 |
| C3d-binding dnDSA | |||||
| No | 123 | 12 | |||
| Yes | 23 | 19 | 11.43 | 5.54–23.59 | <0.001 |
| GSTT genetics recipient (positive vs. null) | |||||
| No | 114 | 20 | |||
| Yes | 32 | 11 | 2.32 | 1.11–4.86 | <0.05 |
| Anti-GSTT Ab (Quartile 4) | |||||
| No | 130 | 20 | |||
| Yes | 16 | 11 | 7.13 | 3.38–15.04 | <0.001 |
*These variables were also analyzed as continuous variables, and results are reported here: recipient age: HR 0.98 (95% CI 0.92–1.04), p = 0.48; donor age: HR 0.64 (95% CI 0.38–1.07), p = 0.09; HLA Ag mismatch: HR 1.32 (95% CI 1.01–1.72), p = 0.04. **Type 1A + borderline changes (bc). CsA, cyclosporine A; Tac, tacrolimus. Bold values represent the statistically significant p-values.